An Update on COVID-19: What the Scientists are Seeing January 7 | Webinar
J.P. Morgan Annual Healthcare ConferenceJanuary 11-14 | Virtual
SOT Annual MeetingMarch 14-18 | Virtual
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorNature Medicine, 2020
Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing…Cell Host Microbe, 2020
Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?
Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 3 therapeutic monoclonal antibodies (MAbs).
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.
Integral Molecular Enables Membrane Protein Antibody Discovery
With a 95% success rate, Integral Molecular is the leader in isolating MAbs against complex membrane proteins, including GPCRs, ion channels, transporters and viral proteins.
With 15+ years experience, Integral Molecular is the industry leader in isolating and characterizing complex membrane proteins.
Integral Molecular’s technologies have contributed to scientific discoveries featured in 200+ peer-reviewed publications.
Your success is crucial to us. We work hard to understand your needs, and strive to exceed your expectations.